1. A FIRST‐IN‐HUMAN TRIAL OF THE NOVEL MULTI‐ACTION THERAPY TINOSTAMUSTINE (EDO‐S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL). (12th June 2019) Authors: Pinto, A.; De Filippi, R.; Zinzani, P.; Driessen, C.; Tun, H.W.; Hilgier, K.; Remmy, D.; Mehrling, T.; O'Connor, O.A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Abnormal transcranial Doppler cerebral blood flow velocity and blood pressure profiles in children with syndromic craniosynostosis and papilledema. Issue 4 (April 2016) Authors: Spruijt, B.; Tasker, R.C.; Driessen, C.; Lequin, M.H.; van Veelen, M.L.C.; Mathijssen, I.M.J.; Joosten, K.F.M. Journal: Journal of cranio-maxillofacial surgery Issue: Volume 44:Issue 4(2016) Page Start: 465 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. (8th April 2019) Authors: Bringhen, S.; Milan, A.; D'Agostino, M.; Ferri, C.; Wäsch, R.; Gay, F.; Larocca, A.; Offidani, M.; Zweegman, S.; Terpos, E.; Goldschmidt, H.; Cavo, M.; Ludwig, H.; Driessen, C.; Auner, H. W.; Caers, J.; Gramatzki, M.; Dimopoulos, M. A.; Boccadoro, M.; Einsele, H. Journal: Journal of internal medicine Issue: Volume 286:Number 1(2019) Page Start: 63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. SAKK 36/13–IBRUTINIB AND BORTEZOMIB FOLLOWED BY IBRUTINIB MAINTENANCE IN PATIENTS WITH RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: PHASE I REPORT OF A PHASE I/II TRIAL. (June 2017) Authors: Novak, U.; Fehr, M.; Zander, T.; Winterhalder, R.; Amram, M.; Stathis, A.; Rondeau, S.; Berardi, S.; Eckhardt, K.; Driessen, C.; Renner, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The first-in-class WASP activator EG-011 is active in lymphoma and multiple myeloma cell lines resistant to FDA approved compounds. (October 2022) Authors: Spriano, F.; Arribas, A.J.; Tarantelli, C.; Sartori, G.; Gaudio, E.; Driessen, C.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗